Originally published as JCO Early Release 10.1200/JCO.2007.15.3106 on May 27 2008

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gorin, N.-C. Articles by Rocha, V. Search for Related Content PubMed PubMed Citation Articles by Gorin, N.-C. Articles by Rocha, V. Social Bookmarking                            What's this?

Identical Outcome After Autologous or Allogeneic Genoidentical Hematopoietic Stem-Cell Transplantation in First Remission of Acute Myelocytic Leukemia Carrying Inversion 16 or t(8;21): A Retrospective Study From the European Cooperative Group for Blood and Marrow Transplantation

Norbert-Claude Gorin, Myriam Labopin, Francesco Frassoni, Noel Milpied, Michel Attal, Didier Blaise, Giovanna Meloni, Anna P. Iori, Mauricette Michallet, Roel Willemze, Eric Deconninck, Jean-Luc Harousseau, Emmanuelle Polge, Vanderson Rocha

From the Department of Hematology, Hôpital Saint Antoine; Acute Leukemia Working Party Registry, European Cooperative Group for Blood and Marrow Transplantation Data and Study Office, Faculté de Médecine St-Antoine Université Pierre et Marie Curie and Institut National de la Santé et de la Recherche Médicale (INSERM) Unit U832; Department of Hematology–Bone Marrow Transplantation (BMT), Hôpital St. Louis, Paris; Centre Hospitalier Universitaire (CHU) Bordeaux Hôpital Haut-Leveque, Pessac; Department of Hematology, Hôpital Purpan CHU, Toulouse; Unité de Transplantation et de Thérapie Cellulaire, Institut Paoli Calmettes, INSERM Unité Medicale de Recherche 599, Marseille; BMT Unit, Hôpital E. Herriot, Lyon; Service d‘Hématologie, Hôpital Jean Minjoz, Besancon; Department of Hematology, Hotel Dieu, Nantes, France; Department of Hematology, Ospedale San Martino, Genova; Dip. Biotecnologie Cellulari ed Ematologia, University La Sapienza, Rome, Italy; and Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands

Corresponding author: Norbert C. Gorin, MD, Hopital Saint-Antoine and Université Pierre et Marie Curie UPMC, 184 Rue du Faubourg Saint-Antoine, Cedex 12 Paris, France 75571; e-mail: norbert-claude.gorin{at}sat.aphp.fr

Purpose Patients with acute myelocytic leukemia carrying inversion 16 (inv16) or t(8;21) have a better initial response to high-dose cytarabine than patients without these chromosomal abnormalities. They presently do not undergo transplantation in first remission (CR1), but there is concern about late relapses.

Patients and Methods From 1990 to 2004, 325 adult patients received transplantations in CR1 (159 patients with inv16 and 166 patients with t(8;21), including 35 and 60 patients, respectively, with additional chromosomal abnormalities). Genoidentical allografts were performed in 64 patients with inv16 and 81 patients with t(8;21), and autografts were performed in 95 patients with inv16 and 85 patients with t(8;21).

Results In patients with inv16, after allogeneic and autologous transplantation, the 5-year leukemia-free survival (LFS) rates were 59% and 66% (P = .5), the relapse incidence (RI) rates were 27% and 32% (P = .45), and the transplantation-related mortality (TRM) rates were 14% and 2% (P = .003), respectively. Female patients had a lower RI and a higher LFS. Additional chromosomal abnormalities, compared with no additional abnormalities, were associated with lower RI rate (12% v 34%, respectively; P = .01) and higher 5-year LFS rate (78% v 59%, respectively; P = .04). In patients with t(8;21), after allogeneic and autologous transplantation, the 5-year LFS rates were 60% and 66% (P = .69), the RI rates were 15% and 28% (P = .03), and the TRM rates were 24% and 6% (P = .003), respectively. Younger age and a lower WBC count at diagnosis were associated with a lower TRM and a better LFS. The TRM was lower and the RI was higher in patients with autologous transplantations versus allogeneic transplantations.

Conclusion Both autologous and allogeneic transplantation resulted in similar outcomes.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

published online ahead of print at www.jco.org on May 27, 2008.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N.-C. Gorin, M. Labopin, D. Blaise, J. Reiffers, G. Meloni, M. Michallet, T. de Witte, M. Attal, B. Rio, F. Witz, et al. Higher Incidence of Relapse With Peripheral Blood Rather Than Marrow As a Source of Stem Cells in Adults With Acute Myelocytic Leukemia Autografted During the First Remission J. Clin. Oncol., August 20, 2009; 27(24): 3987 - 3993. [Abstract] [Full Text] [PDF]